PortfoliosLab logoPortfoliosLab logo
ERNA vs. MLSS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ERNA vs. MLSS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eterna Therapeutics Inc (ERNA) and Milestone Scientific Inc. (MLSS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ERNA achieves a -79.80% return, which is significantly lower than MLSS's 39.89% return. Over the past 10 years, ERNA has underperformed MLSS with an annualized return of -62.07%, while MLSS has yielded a comparatively higher -18.21% annualized return.


ERNA

1D
2.19%
1M
-7.55%
6M
-81.50%
YTD
-79.80%
1Y
-87.57%
3Y*
-81.25%
5Y*
-85.57%
10Y*
-62.07%

MLSS

1D
7.58%
1M
9.11%
6M
29.94%
YTD
39.89%
1Y
-42.69%
3Y*
-29.50%
5Y*
-28.33%
10Y*
-18.21%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ERNA vs. MLSS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ERNA
Eterna Therapeutics Inc
-79.80%-72.79%-83.62%-44.25%-96.14%-6.92%1.82%12.82%-53.68%-50.47%
MLSS
Milestone Scientific Inc.
39.89%-71.56%39.15%43.73%-76.70%-2.83%52.52%319.18%-71.92%-15.64%

Correlation

The correlation between ERNA and MLSS is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Nov 3, 1995

0.06

The correlation between ERNA and MLSS shifts across timeframes, from 0.06 (all time) to 0.17 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ERNA:

$1.90M

MLSS:

$33.78M

EPS

ERNA:

-$23.80

MLSS:

-$0.08

Total Revenue (TTM)

ERNA:

$0.00

MLSS:

$8.93M

Gross Profit (TTM)

ERNA:

-$69.00K

MLSS:

$6.40M

EBITDA (TTM)

ERNA:

-$11.25M

MLSS:

-$6.49M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ERNA vs. MLSS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ERNA
ERNA Risk / Return Rank: 1212
Overall Rank
ERNA Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ERNA Sortino Ratio Rank: 1111
Sortino Ratio Rank
ERNA Omega Ratio Rank: 1313
Omega Ratio Rank
ERNA Calmar Ratio Rank: 55
Calmar Ratio Rank
ERNA Martin Ratio Rank: 1010
Martin Ratio Rank

MLSS
MLSS Risk / Return Rank: 2424
Overall Rank
MLSS Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
MLSS Sortino Ratio Rank: 2626
Sortino Ratio Rank
MLSS Omega Ratio Rank: 2727
Omega Ratio Rank
MLSS Calmar Ratio Rank: 1919
Calmar Ratio Rank
MLSS Martin Ratio Rank: 2525
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ERNA vs. MLSS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eterna Therapeutics Inc (ERNA) and Milestone Scientific Inc. (MLSS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ERNAMLSSDifference
Sharpe ratioReturn per unit of total volatility

-0.09

Sortino ratioReturn per unit of downside risk

-0.81

Omega ratioGain probability vs. loss probability

0.87

0.96

-0.10

Calmar ratioReturn relative to maximum drawdown

-0.94

-0.68

-0.26

Martin ratioReturn relative to average drawdown

-1.38

-0.96

-0.42

ERNA vs. MLSS - Sharpe Ratio Comparison

The current ERNA Sharpe Ratio is -0.58, which is comparable to the MLSS Sharpe Ratio of -0.49. The chart below compares the historical Sharpe Ratios of ERNA and MLSS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ERNA vs. MLSS - Drawdown Comparison

The maximum ERNA drawdown since its inception was -100.00%, roughly equal to the maximum MLSS drawdown of -99.77%. Use the drawdown chart below to compare losses from any high point for ERNA and MLSS.


Loading charts...

Drawdown Indicators


ERNAMLSSDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-99.77%

-0.23%

Max Drawdown (1Y)

Largest decline over 1 year

-93.32%

-63.03%

-30.29%

Max Drawdown (3Y)

Largest decline over 3 years

-99.67%

-81.47%

-18.20%

Max Drawdown (5Y)

Largest decline over 5 years

-100.00%

-90.91%

-9.09%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-94.72%

-5.28%

Current Drawdown

Current decline from peak

-100.00%

-99.55%

-0.45%

Average Drawdown

Average peak-to-trough decline

-86.18%

-91.21%

+5.03%

Ulcer Index

Depth and duration of drawdowns from previous peaks

63.64%

45.28%

+18.36%

Volatility

ERNA vs. MLSS - Volatility Comparison

Eterna Therapeutics Inc (ERNA) and Milestone Scientific Inc. (MLSS) have volatilities of 26.61% and 25.47%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ERNAMLSSDifference

Volatility (1M)

Calculated over the trailing 1-month period

26.61%

25.47%

+1.14%

Volatility (6M)

Calculated over the trailing 6-month period

130.04%

61.75%

+68.29%

Volatility (1Y)

Calculated over the trailing 1-year period

151.77%

88.32%

+63.45%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

114.08%

84.94%

+29.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

149.04%

87.52%

+61.52%

Dividends

ERNA vs. MLSS - Dividend Comparison

Neither ERNA nor MLSS has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ERNA vs. MLSS - Financials Comparison

This section allows you to compare key financial metrics between Eterna Therapeutics Inc and Milestone Scientific Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00K1.00M1.50M2.00M2.50M3.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
2.36M
(ERNA) Total Revenue
(MLSS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ERNA and MLSS have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ERNA has higher volatility (26.61%) compared to MLSS (25.47%). In terms of maximum drawdown, ERNA dropped -100.00% vs MLSS's -99.77%.

MLSS currently has the higher Sharpe Ratio (-0.49 vs -0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ERNA and MLSS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer